Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has requested that preclinical studies on low-dose doxepin be included in the 505(b)(2) application.